Peds week 3

Respiratory anatomy review and key concepts (Asthma intro)

• Respiratory tract structure described as an upside-down tree: trachea is the trunk; primary/secondary/tertiary bronchi; bronchioles; functional units are alveoli (alveolus is singular).

• Gas exchange occurs at the alveolar level: oxygen is taken in, carbon dioxide is blown off.

• Alveolar and capillary membranes are very thin; diffusion enables gas exchange.

• Two main respiratory problems are:

  • Impaired airway clearance (nursing diagnosis 1): air is blocked from reaching the alveoli.

  • Impaired gas exchange (nursing diagnosis 2): air reaches the alveoli but gas exchange is hindered.

• Important clinical mindset: children are not small adults; pediatric respiratory anatomy and physiology differ markedly (e.g., newborns have far fewer alveoli, airway edema in a small airway has a bigger impact).

• Alveolar/alveolar membrane details to remember: alveoli are the site of gas exchange; gaseous diffusion across thin membranes is essential for oxygen uptake and CO₂ elimination.

Key pediatric respiratory anatomy statistics and implications

• Newborn alveoli count: about $10{,}000$.

• By age 10, alveoli count reaches about $2{,}000{,}000$.

• Infant tracheal diameter is very small (diameter of a drinking straw in newborns); even a small amount of edema can critically narrow the airway.

• Swelling in a small airway leads to rapid clinical decompensation in kids due to their limited airway size.

Asthma: pathophysiology and core concepts

• Three processes during an acute asthma exacerbation:

  • Increased mucus production (airway goblet cell hypersecretion and mucous edema)

  • Bronchospasm/bronchoconstriction (smooth muscle constriction around airways)

  • Airway edema (inflammation causing mucosal swelling)

• Mechanism summary: airway inflammation + smooth muscle hyperreactivity + mucus production narrows the lumen and impairs gas exchange.

• Normal airway dynamics: during inhalation, airways bronchodilate; during exhalation, they may constrict a bit; the smooth muscle controls airway diameter.

• Bronchodilation vs bronchoconstriction terminology:

  • Bronchodilation: widening of airways.

  • Bronchoconstriction: narrowing of airways.

• Mucous membrane lining (mucosa) lines the airways; mucus is produced to trap particles; cilia move mucus toward the pharynx to swallow or spit it out.

• Inflammation and edema reduce lumen size; coughing and mucus production further impede airflow.

• Pediatric presentation can include chest tightness, dyspnea, cough, wheeze, anxiety, sweating, and use of accessory muscles.

• Dyspnea definition: difficult or labored breathing; in pediatrics, inability to speak in full sentences is a key sign of distress.

Asthma triggers and risk factors

• Triggers can vary by individual; common categories include:

  • Infections (viral URI)

  • Allergens (pollens like grasses and ragweed; molds when leaves fall)

  • Air irritants (tobacco smoke, pollution)

  • Exercise and cold air

  • Weather and seasonal factors (asthma season aligns with allergy season)

• Risk factors described:

  • Family history of asthma or allergies

  • Male sex in early childhood; females may predominate after puberty

  • Smoky home environments

  • Low birth weight

  • Higher prevalence in certain racial groups (e.g., higher rates in Black families)

  • Obesity

• Triggers are individual; the goal is to identify and avoid triggers and to anticipate them with medications.

• Management principle: prevention and pre-emptive treatment are key to reducing mortality and severe episodes.

• The concept of a clinical pathway (asthma treatment protocol) and an asthma action plan (personalized management plan).

Asthma assessment and monitoring

• Expected findings in an acute episode:

  • Chest tightness, dyspnea

  • Cough with audible wheezing; coarse lung sounds

  • Short, panting speech; inability to speak in complete sentences

  • Anxiety, sweating, use of accessory muscles

• Assessment approach emphasizes rapid recognition of respiratory distress, especially in small children who deteriorate quickly.

• Respiratory rate (RR) is critical but can be hard to measure in children; best practice is to listen with a stethoscope and count breaths for a full minute when possible.

• Vital signs must be interpreted against age-based norms from a reference resource; do not rely on memory alone.

• Cyanosis and poor perfusion (capillary refill, color) indicate hypoxia; give oxygen and escalate care as needed.

• Peak flow testing requires a baseline personal best (green zone) and zone determination to guide therapy.

• Baseline concept: baseline is the patient’s normal, non-exacerbated performance.

Peak flow meters and asthma zones

• Green zone: well-controlled, no symptoms; patient lungs functioning near baseline.

• Yellow zone: caution; partial limitation; symptoms present, risk of escalation.

• Red zone: severe symptoms; dangerous signs; risk of respiratory failure; requires urgent attention.

• Zone thresholds (relative to personal best P_best):

  • Green: 80% and over

    • Yellow: 51-79%

    • Red: 50% or less

• Example: if baseline peak flow is $P_{\text{best}} = 400$, then yellow range is between $200 \,\text{and}\, 320$, green is $P \ge 320$, red is P < 200.

• Personal best is determined by the patient when well; the zone determination uses a quick percentage comparison to this baseline.

Medications for asthma: rescue vs controller; inhaled steroids and other agents

• Codes used to categorize meds:

  • 1: impairment of airway clearance (air cannot reach alveoli) [airway issues]

  • 2: impaired gas exchange (air reaches alveoli but gas exchange is impaired) [gas exchange issues]

  • C: control (daily, preventive meds)

  • R: rescue (relief meds for acute symptoms)

• Bronchodilators (to relieve bronchospasm): target smooth muscle around airways to promote bronchodilation.

  • Short-acting beta-2 agonists (SABAs): Albuterol (rescue med, code R)

  • Ipratropium (a cholinergic antagonist; often used with albuterol in pediatric acute settings; brand Atrovent; adjunct to rescue therapy; code R or combined use)

  • DuoNeb: combination of albuterol + ipratropium (two meds; both intended for acute relief)

  • Non-use of long-acting beta-agonists (not common in pediatrics for short-term rescue)

• Anti-inflammatory agents (preventive and anti-inflammatory effects): target airway inflammation to prevent edema and mucus production.

  • Systemic corticosteroids (short courses for acute exacerbations): Prednisone and Prednisolone; dosage typically $1{-}2\ \,\mathrm{mg/kg}$ per dose, twice daily; prednisone is often given as an oral suspension (prednisolone is the active metabolite; brand example: Orapred).

  • Dexamethasone: potent systemic corticosteroid given as a single dose with effects lasting around $3\ days$; brand example: Decadron; used for croup and some asthma cases; IV or oral.

  • Inhaled corticosteroids (topical, not systemic): Fluticasone (generic) used regularly to prevent symptoms; prevents inflammation with daily dosing; no systemic side effects like oral steroids when used as inhaled therapy.

  • Montelukast (Singulair): leukotriene modifier; taken daily at bedtime (5 mg or 10 mg depending on age/weight); primarily a controller medication; brand Singulair.

• Other meds mentioned:

  • Anticipated use of systemic steroids for acute exacerbations; inhaled steroids for long-term control; leukotriene modifiers for long-term management.

  • Antibiotics for secondary bacterial infections (pneumonia) or severe episodes if indicated.

• Important distinctions:

  • Rescue meds (albuterol, ipratropium, sometimes systemic steroids) are used acutely to reverse symptoms.

  • Controller meds (inhaled corticosteroids like Fluticasone, montelukast, sometimes long-term systemic steroids in specific cases) are used daily to prevent symptoms and reduce inflammation.

• Practical dosing notes:

  • Prednisolone: $1{-}2\ \mathrm{mg/kg/dose}$, twice daily; 3 days is typical; tapering is not required for short courses (≤3 days).

  • Prednisone vs Prednisolone: prednisone is the oral prodrug; prednisolone is the active form used in children (often as a liquid suspension; brand example: Orapred).

  • Dexamethasone: single dose or short course; lasts about $3\ days$ of effect; useful for quick control with fewer doses.

  • Fluticasone: inhaled, daily; controller (topical; not systemic).

  • Montelukast: nightly dose at bedtime; long-term control.

Asthma action plan and clinical pathways

• Asthma action plans are individualized care plans included in discharge paperwork; patients/families should understand triggers, zone interpretation, and actions.

• Green zone: continue daily controller meds; no symptoms.

• Yellow zone: use quick relief meds (rescue inhaler) and consider increased monitoring; may require short-term adjustment of meds per plan.

• Red zone: persistent symptoms or inability to speak; cyanosis or altered mental status; call emergency services (911) or escalate immediately.

• Peak flow zone alignment with actions:

  • Green: self-management with regular controller meds.

  • Yellow: use rescue meds and reassess; may require medical review.

  • Red: urgent care; possible need for hospitalization.

• Practical application: rescue meds may be used in yellow to prevent progression; in red, severe symptoms require immediate intervention.

• The goal of action planning is to recognize problems early and reverse them with pre-planned steps, including medication adjustments and escalation.

Status asthmaticus and complications

• Status asthmaticus: severe, unresponsive asthma attack where the patient does not improve despite treatment; dangerous and requires intensive care.

• In severe cases, there may be little to no wheeze (air movement is severely limited); after bronchodilators, wheezing may reappear as air movement returns.

• Management in status asthmaticus can include IV corticosteroids, terbutaline, magnesium sulfate, nitrous oxide, and potential intensive care with airway support; intubation may be required if airway is obstructed and unresponsive to treatment.

• Overall aim: catch severe episodes early to avoid status asthmaticus and avoid life-threatening respiratory failure.

Spacer/AeroChamber for inhaled meds

• Spacers (aero chambers) with metered-dose inhalers (MDIs) help deliver medication effectively in children by eliminating coordination requirements.

• Use: discharge the inhaler into the spacer, then have the child inhale the medication through a mask or mouthpiece with several deep breaths; can be used even when the child is asleep.

• Rationale: improves medication delivery and reduces user error in pediatric patients.

Cystic fibrosis (CF): overview and clinical features

• CF is an autosomal recessive genetic disorder; two CF gene copies are required for disease expression; carriers have one copy.

• Main pathophysiology: thick, sticky mucus due to defective chloride and sodium transport; mucus is difficult to clear, leading to airway obstruction, infections, and organ damage.

• Primary organ systems affected: lungs (most life-threatening), pancreas (exocrine), and GI tract; also affects reproductive tract.

• Early CF indicators to recognize:

  • Meconium ileus (delayed/meconium passage in newborns)

  • Steatorrhea (fatty, greasy, foul-smelling stools that float)

  • Failure to thrive due to poor fat and protein absorption

• Sweat chloride test: to diagnose CF; an elevated sweat chloride (> $60\ \mathrm{mEq/L}$) supports diagnosis.

• Meconium ileus and CF often correlate with pancreatic insufficiency and malabsorption; early signs help identify CF and improve prognosis with early management.

CF management: lungs, GI, and reproduction

• Respiratory management:

  • Airway clearance therapies to liquefy and mobilize mucus; chest physiotherapy (percussion), postural drainage, and breathing techniques.

  • Chest PT can be time-consuming in practice; alternatives include a vest percussor (mechanical chest therapy) to reduce burden.

  • Nebulized therapies to hydrate and liquefy mucus (e.g., hypertonic saline) and antibiotics for infection control when needed.

  • Dornase alfa (Pulmozyme; DNase) reduces mucus viscosity by breaking down DNA from degraded inflammatory cells; improves mucus clearance.

  • Short-acting bronchodilators (e.g., albuterol) used to open airways and facilitate clearance; combined therapies (e.g., DuoNeb) may be used.

• GI management:

  • Pancreatic enzyme replacement therapy (pancrelipase) with meals and snacks to aid digestion; dosage based on weight/age; give within 30 minutes before meals or with meals; do not give on an empty stomach.

  • Enzyme supplementation improves protein and fat absorption; prevents steatorrhea and failure to thrive.

• Reproductive considerations:

  • Thick cervical mucus and semen can impair fertility; pregnancy is possible but may require additional planning and counseling; contraception and STD protection are important.

• Prognosis and modern treatments:

  • CF care has dramatically improved; patients now live into adulthood with management.

  • Genetic-modifier and targeted therapies (e.g., Trikafta) have transformed outcomes for many CF patients by addressing the underlying genetic defect.

  • Gene-modifying therapies represent a major advancement and illustrate the potential for disease-modifying treatment.

• Historical context and patient perspective:

  • Early CF patients rarely lived past childhood; modern therapy has dramatically improved survival and quality of life.

  • The importance of multidisciplinary care and family education in CF management is emphasized; adherence to enzymes, airway clearance, and therapy regimens is crucial for growth and lung function.

Tonsillitis and tonsillectomy: post-op care

• Tonsillectomy indication: often performed for sleep apnea or large tonsils causing airway obstruction; frequent streptococcal infections may prompt consideration of tonsil/adenoid removal.

• Postoperative priorities after tonsillectomy:

  • ABCs: ensure airway patency and adequate breathing first; monitor for airway compromise.

  • Circulation: maintain hydration; dehydration can worsen perfusion; pain can limit oral intake.

• Pain management and hydration:

  • Administer acetaminophen (Tylenol) around the clock to control pain and facilitate oral intake.

  • Encourage fluids to prevent dehydration; avoid acidic, citrus drinks (e.g., orange juice) that irritate the throat; avoid straws to prevent trauma to the surgical site; limit dairy initially to reduce mucus production.

  • Use non-red popsicles and avoid red foods to prevent misinterpretation of potential bleeding as color changes.

• Hemorrhage risk and signs:

  • Post-op bleeding can occur immediately or around day 5 when scabs fall off; bright red blood, repeated swallowing, vomiting blood, or signs of hypovolemia (hypotension, tachycardia) require urgent attention and possibly re-operation.

  • Immediate reporting to the surgeon if bleeding or airway compromise occurs.

• Parental education and home care:

  • Emphasize pain control and hydration, watch for bleeding signs, and provide clear instructions for when to seek care.

  • School and activity considerations are important; obtain medical notes (e.g., water bottle allowances) as needed.

Common pediatric respiratory infections and conditions

• Streptococcal pharyngitis (strep throat): treated with antibiotics for 10 days; ensure completion of the full course even if symptoms improve early.

• Bronchitis (often viral in teens/adults): supportive care; no antibiotics unless bacterial superinfection suspected.

• Bronchiolitis (infants): typically RSV-driven viral infection; managed with supportive care (hydration, fever management); usually lasts 7–10 days with peak around days 3–5; monitor for signs of respiratory distress; humidified air and elevated head of bed may help; high-risk infants (premature) may require closer monitoring or prophylaxis.

• Pneumonia (bacterial): infection of the alveoli; presents with fever, cough, chest pain, dyspnea, hypoxia; diagnosed clinically with chest X-ray confirming consolidation; treated with antibiotics; IV antibiotics for hospitalized or severely ill children.

• Croup syndromes:

  • Croup (laryngotracheobronchitis): viral; presents with a barky cough and inspiratory stridor; treat with cool mist humidifier, fluids, and steroids; most recover with supportive care.

  • Bacterial epiglottitis: emergency; typically due to Haemophilus influenzae type b (HIB) vaccination reduces incidence; requires IV antibiotics and steroids; airway management preparedness is crucial; emergency airway equipment and readiness for potential intubation or cricothyrotomy.

• RSV immunoprophylaxis:

  • Monoclonal antibodies for RSV are used in high-risk infants to prevent severe disease; not given to all babies; targeted prophylaxis for susceptible populations.

Practical clinical pearls and nursing tips

• Always consider the worst-case scenario for each patient (clinical judgment) and prioritize the sickest patient first.

• Use clinical pathways and asthma action plans to standardize care and empower families to manage illness at home.

• In asthma care, distinguish rescue vs controller medications clearly and teach families how and when to use each.

• In inhaled therapy, spacers improve delivery efficiency and safety; teach families how to use MDIs with spacers correctly.

• For CF, early identification and aggressive airway clearance are critical; emphasize pancreatic enzyme replacement with every meal and snack; ensure adherence to therapies to optimize growth and lung function.

• After tonsillectomy, emphasize airway safety, pain control, and hydration; monitor for signs of hemorrhage; educate families about when to seek urgent care.

• Recognize red flags that require urgent evaluation: cyanosis, severe respiratory distress, inability to speak, drooling or mental status changes in epiglottitis, and signs of impending airway collapse.

Quick reference variables and formulas

• Gases of respiration:

  • Oxygen: $O_2$

  • Carbon dioxide: $CO_2$

• Alveolar gas exchange and diffusion depend on thin membranes and capillaries enabling gas diffusion.

• Alveoli numbers: newborn ≈ $10{,}000$; by age 10 ≈ $2{,}000{,}000$.

• Asthma zone thresholds relative to personal best $P_{best}$:

  Medication dosing examples:

  • Prednisolone: $1{-}2\ \mathrm{mg/kg}$ per dose, twice daily (3 days typical)

  • Prednisolone vs prednisone: prednisone is the prodrug; prednisolone is the active liquid form (Orapred)

  • Dexamethasone: single dose or short course; lasts ~$3\ days$; brand Decadron

  • Montelukast: nightly dose (5 or 10 mg depending on age); controller

  • Fluticasone: inhaled corticosteroid; controller; daily use; topical not systemic

  • Pancrelipase: enzyme replacement; given with meals/snacks; not on an empty stomach; dose individualized per weight/age

  • Dornase alfa (Pulmozyme): mucus liquefier via inhalation

Final take-home messages

• Respiratory care in pediatrics hinges on early recognition, rapid assessment, and clear action plans to prevent deterioration.

• Understanding the distinct roles of bronchodilators (rescue) and anti-inflammatory/controller medications is essential for safe and effective asthma management.

• CF requires a comprehensive, multidisciplinary approach focused on airway clearance, nutrition, and prevention of infection; advances in therapy have markedly improved survival and quality of life.

• Postoperative and infectious respiratory care rely on airway safety, pain control, hydration, and family education to ensure safe recovery and proper home management.